Standard Quality Characteristics and Efficacy of a New Third-Generation Antivenom Developed in Colombia Covering

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

1. Brief history of ophidiology and ophidism in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026
   Review
2. In-Depth Multi-Assembler Venom-Gland Transcriptomics of Three Medically Important Colombian Snakes Highlights Diversity of Accessory, Low-Abundance Protein Families.Toxins · 2026
   Article
3. First characterization of the venom of the endemic coral snake Micrurus camilae (Serpentes: Elapidae) from Colombia: Proteome, toxic activities, immunorecognition, and neutralization by antivenoms.PLoS neglected tropical diseases · 2026
   Article
4. Obtention and preliminary clinical evaluation of an equine albumin for intravenous administration in adult Colombian Creole Horses (Equus ferus caballus).PloS one · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 3 institutions in 1 country.

Funding

Abstract

Indexed as